本文へ移動
cccskills
無料GitHub で公開

enda-adjust-glucocorticoid-clinical-response

The Endocrine Society guideline recommends against routine hormonal monitoring of glucocorticoid replacement in primary adrenal insufficiency and advises adjusting therapy solely based on clinical response. Use when evaluating glucocorticoid dose adequacy, such as when patients report fatigue, weight loss, hypotension, or signs of Cushingoid over-replacement.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md2.2 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Adjust Glucocorticoid Treatment Based Solely on Clinical Response

STEP 1 — Gather Information

Collect clinical symptoms and signs of glucocorticoid over- or under-replacement: weight change, appetite, energy levels, blood pressure, peripheral edema, hyperpigmentation, and patient-reported well-being.

STEP 2 — Rule In / Rule Out

Is there clinical evidence of glucocorticoid excess or deficiency? If yes, proceed to classification; if no, maintain current dose and reassess in 4–6 weeks.

STEP 3 — Classify or Stratify

Classify as over-replacement (Cushingoid signs: weight gain, insomnia, peripheral edema, etc.), under-replacement (fatigue, weight loss, hypotension, hyperpigmentation, etc.), or adequate (stable weight, normal energy, no symptoms).

STEP 4 — Decide

If over-replacement, reduce glucocorticoid dose by 2.5–5 mg hydrocortisone equivalent; if under-replacement, increase dose by 2.5–5 mg; if adequate, continue current regimen.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on ACTH or cortisol levels to guide dosing; avoid over-reliance on hormonal monitoring. Symptoms can be nonspecific—consider concurrent illness, stress, or pregnancy. Avoid abrupt dose changes; taper adjustments. Monitor for signs of adrenal crisis during dose reduction.

Concrete Clinical Example

A 48-year-old man on hydrocortisone 15 mg daily reports progressive fatigue and 3 kg weight loss over 2 months, with postural hypotension; no Cushingoid signs. Clinical assessment suggests under-replacement; dose increased to 20 mg daily, with symptom reassessment scheduled in 4 weeks.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI: 10.1210/jc.2015-1710

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する